is a biotech company dedicated to transforming the cardio-renal disease treatment paradigm by focusing on the reducing the risk and treatment of kidney disease.
This includes reducing the risk of post operative complications in patients undergoing cardiothoracic surgery which represents a significant unmet medical need and results in high morbidity, mortality, and costs to the healthcare system.
- 36% of patients experience major postoperative complications after cardiac surgery.
Intensive care after a cardiothoracic surgery is a standard component of the treatment for most of the patients. However, a long intensive care stay results in increased hospital mortality, poor long-term prognosis, increased morbidity, increased hospital days, and consequently, increased cost and expenses.
- Up to 36% of patients undergoing cardiac surgery have a long (> 36 hours) postoperative stay in intensive care unit.
- This results in failure of some organs, an increase in mortality rates as well as higher utilization of healthcare resources
Each year, 9 million U.S. adults suffer from acute kidney injury (AKI) and today, 37 million U.S. adults are living with chronic kidney disease (CKD). It is also associated with a higher risk of mortality in both inpatient and outpatient settings, and progression to CKD within 24 months occurs in approximately 15-20% of patients who survive AKI.
The quality of life and financial burdens of AKI and CKD have reached insurmountable proportions for patients and their families. Unfortunately, there are currently no approved therapies that reduce the risk or treat AKI.
